| scholarly article | Q13442814 |
| P50 | author | Andy Diamos | Q29046794 |
| Jacquelyn Kilbourne | Q91845499 | ||
| Hugh S Mason | Q52655688 | ||
| P2093 | author name string | Kenneth E Palmer | |
| Lauren Brown | |||
| Divyasha Saxena | |||
| Dalia Larios | |||
| Hyun Soon Kim | |||
| P2860 | cites work | The potential of plants as a system for the development and production of human biologics | Q26747611 |
| Single-step assembly of a gene and entire plasmid from large numbers of oligodeoxyribonucleotides | Q28291604 | ||
| Recognition of immunoglobulins by Fcgamma receptors | Q28610394 | ||
| Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant | Q30224854 | ||
| Expression of an immunogenic Ebola immune complex in Nicotiana benthamiana. | Q33619065 | ||
| Manufacturing economics of plant-made biologics: case studies in therapeutic and industrial enzymes | Q33757315 | ||
| Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6 | Q33816200 | ||
| A nonreplicating subunit vaccine protects mice against lethal Ebola virus challenge. | Q34029668 | ||
| Highly immunogenic and protective recombinant vaccine candidate expressed in transgenic plants. | Q34033969 | ||
| Increased efficacy of the immunoglobulin G2a subclass in antibody-mediated protection against lactate dehydrogenase-elevating virus-induced polioencephalomyelitis revealed with switch mutants | Q34327111 | ||
| HPV vaccine: an overview of immune response, clinical protection, and new approaches for the future | Q34335370 | ||
| HBV core particles as a carrier for B cell/T cell epitopes | Q34339579 | ||
| Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. | Q34417608 | ||
| Controlled glycosylation of plant-produced recombinant proteins | Q34428161 | ||
| Murine Fc receptors for IgG are redundant in facilitating presentation of immune complex derived antigen to CD8+ T cells in vivo | Q58234959 | ||
| HPV: The global burden | Q59062791 | ||
| Binding characteristics of three complement dependent assays for the detection of immune complexes in human serum | Q69877785 | ||
| Activation of mouse complement by monoclonal mouse antibodies | Q71064651 | ||
| Production of papillomavirus-based gene transfer vectors | Q80568642 | ||
| Tandem fusion of hepatitis B core antigen allows assembly of virus-like particles in bacteria and plants with enhanced capacity to accommodate foreign proteins | Q35591846 | ||
| Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2. | Q36314993 | ||
| A protective and broadly cross-neutralizing epitope of human papillomavirus L2. | Q36315086 | ||
| Virally induced modulation of murine IgG antibody subclasses | Q36355787 | ||
| Expression and role of Fc- and complement-receptors on human dendritic cells. | Q36382833 | ||
| Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. | Q36545925 | ||
| 5' and 3' Untranslated Regions Strongly Enhance Performance of Geminiviral Replicons in Nicotiana benthamiana Leaves | Q36610383 | ||
| The position of heterologous epitopes inserted in hepatitis B virus core particles determines their immunogenicity | Q36655876 | ||
| Human papillomavirus molecular biology and disease association | Q37257349 | ||
| An efficient plant viral expression system generating orally immunogenic Norwalk virus-like particles | Q37348115 | ||
| Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic | Q37353496 | ||
| Glycosylation as a strategy to improve antibody-based therapeutics | Q37402407 | ||
| The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding | Q37453403 | ||
| The use of immune complex vaccines to enhance antibody responses against neutralizing epitopes on HIV-1 envelope gp120. | Q37462829 | ||
| Use of hepadnavirus core proteins as vaccine platforms | Q37622906 | ||
| Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy | Q37725351 | ||
| Glyco-engineering in plants to produce human-like N-glycan structures | Q38034471 | ||
| FcR gamma chain deletion results in pleiotrophic effector cell defects | Q38311129 | ||
| The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years | Q38383530 | ||
| Novel vaccination approach for dengue infection based on recombinant immune complex universal platform | Q38904898 | ||
| Developments in L2-based human papillomavirus (HPV) vaccines | Q39021001 | ||
| High-level rapid production of full-size monoclonal antibodies in plants by a single-vector DNA replicon system | Q40369680 | ||
| Epitopes involved in antibody-mediated protection from Ebola virus | Q40625468 | ||
| A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9-15-Year-Old Girls. | Q41151166 | ||
| Role of the B-cell response in recovery of mice from primary influenza virus infection | Q41672946 | ||
| Recombinant immune complexes as versatile and potent vaccines. | Q41812053 | ||
| A DNA replicon system for rapid high-level production of virus-like particles in plants | Q42200961 | ||
| Techno-economic analysis of a transient plant-based platform for monoclonal antibody production | Q42373048 | ||
| Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region | Q43605407 | ||
| Plant-derived recombinant immune complexes as self-adjuvanting TB immunogens for mucosal boosting of BCG. | Q44512209 | ||
| Vaccination of cattle with bovine papillomavirus type 4 L2 elicits the production of virus-neutralizing antibodies | Q45768978 | ||
| Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure | Q46697395 | ||
| Plant-expressed Fc-fusion protein tetravalent dengue vaccine with inherent adjuvant properties. | Q47265866 | ||
| N-glycan engineering of a plant-produced anti-CD20-hIL-2 immunocytokine significantly enhances its effector functions | Q47311471 | ||
| An intronless form of the tobacco extensin gene terminator strongly enhances transient gene expression in plant leaves. | Q50078833 | ||
| Conformational analysis of hepatitis B surface antigen fusions in an Agrobacterium-mediated transient expression system. | Q50705974 | ||
| A polymeric immunoglobulin - antigen fusion protein strategy for enhancing vaccine immunogenicity. | Q52312992 | ||
| Foreign epitopes in immunodominant regions of hepatitis B core particles are highly immunogenic and conformationally restricted | Q53858251 | ||
| Roles of Fc domain and exudation in L2 antibody-mediated protection against human papillomavirus. | Q54216752 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 137-144 | |
| P577 | publication date | 2018-11-17 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | Vaccine synergy with virus-like particle and immune complex platforms for delivery of human papillomavirus L2 antigen | |
| P478 | volume | 37 |
| Q90335301 | Codelivery of improved immune complex and virus-like particle vaccines containing Zika virus envelope domain III synergistically enhances immunogenicity |
| Q89497585 | High Level Production of Monoclonal Antibodies Using an Optimized Plant Expression System |
| Q91828989 | Recombinant Viral Capsid Protein L2 (rVL2) of HPV 16 Suppresses Cell Proliferation and Glucose Metabolism via ITGB7/C/EBPβ Signaling Pathway in Cervical Cancer Cell Lines |
| Q98502794 | Targeting HIV Env immunogens to B cell follicles in nonhuman primates through immune complex or protein nanoparticle formulations |
| Q92257210 | Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today? |
Search more.